Regulatory Approval Oncology GLP-1 Agonists Anti-IL-11 Drugs HIV Treatments Antimicrobial Resistance Impairment Loss Ethical Concerns Precision Medicine AstraZeneca Global Health Orforglipron Weight Loss Medications FDA Approval Autoimmune Diseases siRNA Therapy Treatment Efficacy Therapeutic Applications Boehringer Ingelheim Monoclonal Antibodies Phase Trials COPD Treatments Pipeline Management RAS(ON) Inhibitors Weight Management Preclinical Research Antibody Therapy Phase 3 Trials Ionis Pharmaceuticals Cardiovascular Drugs
Want to see what podcasts are saying about this topic? Search across 165K+ podcasts. Explore Radar
The company says it referred more than 200 people and entities to regulators to stop unsafe illicit GLP‑1 sales ahead of a planned Q1 2027 U.S. biologics filing for retatrutide.
